Precursor lesions of ovarian epithelial malignancy

Histopathology
38, 87-95
DOI: 10.1046/j.1365-2559.2001.01042.x

Citation Report

#	Article	IF	Citations
1	Molecular targets for epithelial ovarian cancer. , 0, , 606-618.		0
2	Aberrant expression of homeobox gene HOXA7 is associated with mullerian-like differentiation of epithelial ovarian tumors and the generation of a specific autologous antibody response. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 15209-15214.	3.3	82
3	Roles of the ovarian surface epithelium in ovulation and carcinogenesis. Reproduction, 2002, 123, 743-750.	1.1	148
4	Non-neoplastic diseases of the ovary: selected topics. Current Diagnostic Pathology, 2002, 8, 172-182.	0.4	1
5	Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell, 2002, 1, 53-62.	7.7	330
6	Changes in the mouse ovarian surface epithelium with age and ovulation number. Molecular and Cellular Endocrinology, 2002, 191, 105-111.	1.6	32
7	Molecular classification of borderline ovarian tumors using hierarchical cluster analysis of protein expression profiles. International Journal of Cancer, 2002, 98, 895-899.	2.3	59
8	Possible involvement ofhMLH1, p16INK4a andPTEN in the malignant transformation of endometriosis. International Journal of Cancer, 2002, 102, 398-406.	2.3	128
9	Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity. Cancer, 2002, 94, 2380-2392.	2.0	71
10	Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis. Cancer, 2002, 95, 1802-1815.	2.0	52
11	Epithelial Abnormalities in Cystic Ovarian Endometriosis. Gynecologic Oncology, 2002, 84, 280-284.	0.6	94
12	The dominance of the microenvironment in breast and ovarian cancer. Seminars in Cancer Biology, 2002, 12, 97-104.	4.3	113
13	Ovarian cancer and high-risk womenâ€"implications for prevention, screening, and early detection. Gynecologic Oncology, 2003, 91, 15-31.	0.6	58
14	Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies. Cancer, 2003, 98, 2607-2623.	2.0	60
15	Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition. Histopathology, 2003, 43, 26-32.	1.6	38
16	Lack of proliferative activity of surface epithelial inclusion cysts of the ovary. International Journal of Gynecological Cancer, 2003, 13, 303-307.	1.2	15
17	Translational research in ovarian cancer: a must. International Journal of Gynecological Cancer, 2003, 13, 220-230.	1.2	11
18	Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells. Oncogene, 2003, 22, 4243-4256.	2.6	33

#	Article	IF	Citations
19	K-RAS Mutations in Ovarian and Extraovarian Lesions of Serous Tumors of Borderline Malignancy. Laboratory Investigation, 2003, 83, 251-258.	1.7	44
20	Loss of Cables, a Novel Gene on Chromosome 18q, in Ovarian Cancer. Modern Pathology, 2003, 16, 863-868.	2.9	21
21	The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer. Reproductive Biology and Endocrinology, 2003, 1, 72.	1.4	36
22	Expression Profiling in Ovarian Clear Cell Carcinoma. American Journal of Pathology, 2003, 163, 2503-2512.	1.9	292
23	Amplification and Overexpression of the L-MYC Proto-Oncogene in Ovarian Carcinomas. American Journal of Pathology, 2003, 162, 1603-1610.	1.9	63
24	Metaplastic potential of p53 down-regulation in ovarian surface epithelial cells affected by ovulation. Cancer Letters, 2003, 191, 75-81.	3.2	15
25	Abdominal pain during pregnancy. Gastroenterology Clinics of North America, 2003, 32, 1-58.	1.0	121
26	Challenges in the Early Diagnosis and Staging of Fallopian-Tube Carcinomas Associated with BRCA Mutations. International Journal of Gynecological Pathology, 2003, 22, 109-120.	0.9	54
27	Title is missing!. Current Opinion in Obstetrics and Gynecology, 2003, 15, 321-326.	0.9	8
28	Wilms Tumor Gene Immunoreactivity in Primary Serous Carcinomas of the Fallopian Tube, Ovary, Endometrium, and Peritoneum. International Journal of Gynecological Pathology, 2003, 22, 374-377.	0.9	111
29	Ovarian endometriosis. Current Opinion in Obstetrics and Gynecology, 2003, 15, 321-326.	0.9	98
30	Inhibitory Effects of Progesterone on Plasma Membrane Fluidity and Tumorigenic Potential of Ovarian Epithelial Cancer Cells. Experimental Biology and Medicine, 2003, 228, 308-314.	1.1	29
31	Potential for TRAIL as a Therapeutic Agent in Ovarian Cancer. Vitamins and Hormones, 2004, 67, 347-364.	0.7	11
32	Epigenetic Inactivation of TMS1/ASC in Ovarian Cancer. Clinical Cancer Research, 2004, 10, 2000-2006.	3.2	85
33	WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology, 2004, 44, 109-115.	1.6	234
34	Malignant mixed mullerian tumour of the fallopian tube occurring in a patient with Peutz-Jegher's syndrome. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2004, 44, 77-79.	0.4	7
35	Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene, 2004, 23, 8171-8183.	2.6	75
36	Molecular genetic analysis of ovarian serous cystadenomas. Laboratory Investigation, 2004, 84, 778-784.	1.7	53

#	Article	IF	Citations
37	Focus on epithelial ovarian cancer. Cancer Cell, 2004, 5, 19-24.	7.7	267
38	Cell cycle and apoptotic proteins in relation to ovarian epithelial morphology. Gynecologic Oncology, 2004, 92, 247-251.	0.6	17
39	Cyclooxygenase-2 expression in borderline ovarian tumors. Gynecologic Oncology, 2004, 95, 46-51.	0.6	10
40	Intraperitoneal serous adenocarcinoma: A critical appraisal of three hypotheses on its cause. American Journal of Obstetrics and Gynecology, 2004, 191, 718-732.	0.7	104
41	Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations. Familial Cancer, 2004, 3, 265-281.	0.9	35
42	A multistep model for ovarian tumorigenesis: the value of mutation analysis in theKRAS andBRAF genes. Journal of Pathology, 2004, 203, 617-619.	2.1	76
43	Diagnostic and molecular genetic pathology of serous borderline tumours of the ovary. Current Diagnostic Pathology, 2004, 10, 318-325.	0.4	4
44	Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Human Pathology, 2004, 35, 552-559.	1.1	134
46	Recent Advances in Endometriosis With Emphasis on Pathogenesis, Molecular Pathology, and Neoplastic Transformation. International Journal of Gynecological Pathology, 2004, 23, 316-320.	0.9	34
47	Oxidative Damage to DNA of Ovarian Surface Epithelial Cells Affected by Ovulation: Carcinogenic Implication and Chemoprevention. Experimental Biology and Medicine, 2004, 229, 546-552.	1.1	97
48	6 K-Ras Mutations in Serous Borderline Tumors of the Ovary. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2005, 4, 357-361.	0.0	0
49	Histologic Type, Organ of Origin, and Wnt Pathway Status: Effect on Gene Expression in Ovarian and Uterine Carcinomas. Clinical Cancer Research, 2005, 11, 2123-2131.	3.2	44
50	Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis. American Journal of Surgical Pathology, 2005, 29, 218-224.	2.1	388
51	An Immunohistochemical Comparison Between Low-Grade and High-Grade Ovarian Serous Carcinomas. American Journal of Surgical Pathology, 2005, 29, 1034-1041.	2.1	155
52	Prevalence and histologic diagnosis of adnexal cysts in postmenopausal women: An autopsy study. American Journal of Obstetrics and Gynecology, 2005, 192, 48-54.	0.7	74
53	Emerging issues of the expression profiling technologies for the study of gynecologic cancer. American Journal of Obstetrics and Gynecology, 2005, 193, 908-918.	0.7	9
54	Overexpression of cyclin D1 and c-Myc gene products in human primary epithelial ovarian cancer. International Journal of Gynecological Cancer, 2005, 15, 878-883.	1.2	59
55	Serous borderline tumours of the ovary. Histopathology, 2005, 47, 310-315.	1.6	58

#	Article	IF	Citations
56	Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nature Medicine, 2005, 11, 531-537.	15.2	265
57	Ovarian Cancer Metastasis: Integrating insights from disparate model organisms. Nature Reviews Cancer, 2005, 5, 355-366.	12.8	480
58	Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: Correlation with histopathology. Gynecologic Oncology, 2005, 99, 367-375.	0.6	15
59	Expression of estrogen-responsive finger protein (Efp) is associated with advanced disease in human epithelial ovarian cancer. Gynecologic Oncology, 2005, 99, 664-670.	0.6	33
60	Differential expression ofProtease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. International Journal of Cancer, 2005, 113, 372-378.	2.3	101
61	Centrosome abnormalities in ovarian cancer. International Journal of Cancer, 2005, 113, 746-751.	2.3	46
62	Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours. Journal of Surgical Oncology, 2005, 92, 337-343.	0.8	24
63	Location of inclusion cysts in mouse ovaries in relation to age, pregnancy, and total ovulation number: implications for ovarian cancer?. Journal of Pathology, 2005, 205, 483-490.	2.1	36
64	Microarray Comparative Genomic Hybridization Profile of a Murine Model for Epithelial Ovarian Cancer Reveals Genomic Imbalances Resembling Human Ovarian Carcinomas. Tumor Biology, 2005, 26, 236-244.	0.8	19
65	Differential Expression of Laminin Isoforms in Ovarian Epithelial Carcinomas Suggesting Different Origin and Providing Tools for Differential Diagnosis. Journal of Histochemistry and Cytochemistry, 2005, 53, 1293-1300.	1.3	17
66	Overexpression of Cytochrome P450 1A1 and Its Novel Spliced Variant in Ovarian Cancer Cells: Alternative Subcellular Enzyme Compartmentation May Contribute to Carcinogenesis. Cancer Research, 2005, 65, 3726-3734.	0.4	49
67	Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer. Clinical Cancer Research, 2005, 11, 6422-6430.	3.2	349
68	Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges. Clinical Cancer Research, 2005, 11, 7273-7279.	3.2	131
69	Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Women's Oncology Review, 2005, 5, 219-221.	0.0	0
70	Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon. Clinical Cancer Research, 2005, 11, 6116-6126.	3.2	283
71	Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian Carcinomas. Cancer Research, 2005, 65, 2162-2169.	0.4	484
72	Ovarian cancer, the coagulation pathway, and inflammation. Journal of Translational Medicine, 2005, 3, 25.	1.8	102
73	Carcinogenic Potential of Ovulatory Genotoxicity1. Biology of Reproduction, 2005, 73, 586-590.	1.2	40

#	Article	IF	Citations
74	Disabled-2 Heterozygous Mice Are Predisposed to Endometrial and Ovarian Tumorigenesis and Exhibit Sex-Biased Embryonic Lethality in a p53-Null Background. American Journal of Pathology, 2006, 169, 258-267.	1.9	28
75	Histopathological challenges in assessing borderline ovarian tumours. Current Diagnostic Pathology, 2006, 12, 325-346.	0.4	3
76	The role of gene expression profiling in the clinical management of ovarian cancer. European Journal of Cancer, 2006, 42, 2930-2938.	1.3	19
77	Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: Revisiting old hypotheses. Molecular and Cellular Endocrinology, 2006, 247, 4-21.	1.6	162
78	GENE EXPRESSION DATA ANALYSIS IN SUBTYPES OF OVARIAN CANCER USING COVARIANCE ANALYSIS. Journal of Bioinformatics and Computational Biology, 2006, 04, 999-1014.	0.3	4
79	Magnetic Resonance Imaging of Adnexal Masses. Topics in Magnetic Resonance Imaging, 2006, 17, 379-397.	0.7	19
80	Immunohistochemical and Functional Biomarkers of Value in Female Genital Tract Lesions. International Journal of Gynecological Pathology, 2006, 25, 101-120.	0.9	65
81	Classifications of ovarian cancer tissues by proteomic patterns. Proteomics, 2006, 6, 5846-5856.	1.3	41
82	Irregularly shaped inclusion cysts display increased expression of Ki67, Fas, Fas ligand, and procaspase-3 but relatively little active caspase-3. International Journal of Gynecological Cancer, 2006, 16, 231-239.	1.2	11
83	Higher frequency of chromosomal aberrations in ovarian endometriosis compared to extragonadal endometriosis: a possible link to endometrioid adenocarcinoma. Modern Pathology, 2006, 19, 1615-1623.	2.9	31
84	Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy. Gynecologic Oncology, 2006, 103, 405-416.	0.6	104
85	Ovarian epithelial tumors of low malignant potential: Are they precursors of ovarian carcinoma?. Pathology International, 2006, 56, 233-239.	0.6	20
86	A distinct molecular profile associated with mucinous epithelial ovarian cancer. British Journal of Cancer, 2006, 94, 904-913.	2.9	102
87	My approach to and thoughts on the typing of ovarian carcinomas. Journal of Clinical Pathology, 2007, 61, 152-163.	1.0	141
88	Î±2Î²1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. Journal of Carcinogenesis, 2007, 6, 11.	2.5	103
89	A system-wide analysis of differentially expressed genes in ectopic and eutopic endometrium. Human Reproduction, 2007, 22, 2093-2102.	0.4	41
90	CA125 in ovarian cancer. Biomarkers in Medicine, 2007, 1, 513-523.	0.6	164
91	Ovarian Epithelial Inclusion Cysts in Chronically Superovulated CD1 and Smad2 Dominant-Negative Mice. Endocrinology, 2007, 148, 3595-3604.	1.4	19

#	Article	IF	Citations
92	Characterization of a preclinical model of simultaneous breast and ovarian cancer progression. Carcinogenesis, 2007, 28, 130-135.	1.3	20
93	HOXA7 in Epithelial Ovarian Cancer: Interrelationships Between Differentiation and Clinical Features. Reproductive Sciences, 2007, 14, 605-614.	1.1	25
94	The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms. Expert Reviews in Molecular Medicine, 2007, 9, 1-12.	1.6	37
95	Clear Cell Adenocarcinoma Associated With Clear Cell Adenofibromatous Components: A Subgroup of Ovarian Clear Cell Adenocarcinoma With Distinct Clinicopathologic Characteristics. American Journal of Surgical Pathology, 2007, 31, 999-1006.	2.1	57
96	Small Cell Carcinoma of Pulmonary Type Inside a Microinvasive Mucinous Cystadenocarcinoma of the Ovary. International Journal of Gynecological Pathology, 2007, 26, 426-431.	0.9	23
97	Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Letters, 2007, 247, 130-136.	3.2	57
98	Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment. Cancer Letters, 2007, 255, 263-274.	3.2	59
99	MicroRNA Signatures in Human Ovarian Cancer. Cancer Research, 2007, 67, 8699-8707.	0.4	1,356
100	Large-Scale Proteomics Analysis of Human Ovarian Cancer for Biomarkers. Journal of Proteome Research, 2007, 6, 1440-1450.	1.8	75
101	The Continuum of Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary. Disease Markers, 2007, 23, 377-387.	0.6	23
102	Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis. Molecular Carcinogenesis, 2007, 46, 130-143.	1.3	31
103	High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology, 2007, 50, 773-779.	1.6	90
104	Atypical mucinous metaplasia and intraepithelial neoplasia of the female genital tractâ€"a case report and review of the literature. International Journal of Gynecological Cancer, 2007, 17, 1147-1150.	1.2	20
105	Overexpression of mammaglobin B in epithelial ovarian carcinomas. Gynecologic Oncology, 2007, 105, 578-585.	0.6	28
106	Evaluation of normal-sized ovaries associated with primary peritoneal serous carcinoma for possible precursors of ovarian serous carcinoma. Gynecologic Oncology, 2007, 106, 201-206.	0.6	18
107	A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17. Journal of Immunological Methods, 2007, 321, 86-93.	0.6	25
108	Lysophosphatidic acid activates telomerase in ovarian cancer cells through hypoxiaâ€inducible factorâ€1Î± and the PI3K pathway. Journal of Cellular Biochemistry, 2008, 105, 1194-1201.	1.2	29
109	Genomic analysis of epithelial ovarian cancer. Cell Research, 2008, 18, 538-548.	5.7	62

#	Article	IF	Citations
110	Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Modern Pathology, 2008, 21, 676-684.	2.9	91
111	The morphogenic function of E-cadherin-mediated adherens junctions in epithelial ovarian carcinoma formation and progression. Differentiation, 2008, 76, 193-205.	1.0	45
112	Germ cell specific protein VASA is over-expressed in epithelial ovarian cancer and disrupts DNA damage-induced G2 checkpoint. Gynecologic Oncology, 2008, 111, 312-319.	0.6	35
115	Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncology, The, 2008, 9, 1076-1085.	5.1	97
116	Analysis of Gene Expression in Early-Stage Ovarian Cancer. Clinical Cancer Research, 2008, 14, 7850-7860.	3.2	43
117	Learning about ovarian tumorigenesis by watching Cables. Cancer Biology and Therapy, 2008, 7, 189-190.	1.5	1
118	Early detection of ovarian cancer. Biomarkers in Medicine, 2008, 2, 291-303.	0.6	74
119	Pathogenesis of Ovarian Cancer. International Journal of Gynecological Pathology, 2008, PAP, 151-60.	0.9	385
120	WT1 expression in endometrioid ovarian carcinoma with and without associated endometriosis. Pathology, 2008, 40, 592-599.	0.3	26
121	Sperm Protein 17 is a Suitable Target for Adoptive T-cellâ€"based Immunotherapy in Human Ovarian Cancer. Journal of Immunotherapy, 2008, 31, 693-703.	1.2	21
122	Molecular Pathogenesis of Epithelial Ovarian Cancer. , 2008, , 441-454.		1
123	Expression of the Epidermal Growth Factor Receptor Family in Correlation to the Estrogen Receptor Î± Expression in Peritoneal and Ovarian Endometriosis. Journal of Endometriosis, 2009, 1, 122-130.	1.0	0
124	The Expression and Significance of Dickkopf-1 in Epithelial Ovarian Carcinoma. International Journal of Biological Markers, 2009, 24, 165-170.	0.7	17
125	Genetically Engineered Mouse Models of Ovarian Cancer and Their Utility in Drug Discovery. Current Protocols in Pharmacology, 2009, 45, Unit14.11.	4.0	3
126	Chapter 6 Translational Control During Early Development. Progress in Molecular Biology and Translational Science, 2009, 90, 211-254.	0.9	19
127	Possible angiogenic roles for claudin-4 in ovarian cancer. Cancer Biology and Therapy, 2009, 8, 1806-1814.	1.5	32
128	Pattern of retroperitoneal dissemination of primary peritoneum cancer: Basis for rational use of lymphadenectomy. Gynecologic Oncology, 2009, 114, 32-36.	0.6	17
129	Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma. Modern Pathology, 2009, 22, 197-205.	2.9	80

#	Article	IF	Citations
130	The biology of ovarian cancer: new opportunities for translation. Nature Reviews Cancer, 2009, 9, 415-428.	12.8	1,172
131	The Mammalian Ovary from Genesis to Revelation. Endocrine Reviews, 2009, 30, 624-712.	8.9	630
132	Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors. Human Pathology, 2009, 40, 965-974.	1.1	40
133	Ovarian Cancer. Annual Review of Pathology: Mechanisms of Disease, 2009, 4, 287-313.	9.6	576
134	Inflammatory Cytokine Tumor Necrosis Factor Î± Confers Precancerous Phenotype in an Organoid Model of Normal Human Ovarian Surface Epithelial Cells. Neoplasia, 2009, 11, 529-541.	2.3	48
135	The Role of Hepatocyte Nuclear Factor-1Î² in the Pathogenesis of Clear Cell Carcinoma of the Ovary. International Journal of Gynecological Cancer, 2009, 19, 471-479.	1.2	60
136	miR-29b Expression Is Associated With Disease-Free Survival in Patients With Ovarian Serous Carcinoma. International Journal of Gynecological Cancer, 2009, 19, 641-647.	1.2	55
138	Expression of the Retinoblastoma-related Gene Rb2/p130 in the Pathogenesis of Serous Carcinoma of the Ovary. Applied Immunohistochemistry and Molecular Morphology, 2010, 18, 509-511.	0.6	2
140	Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors. Journal of Cancer Research and Clinical Oncology, 2010, 136, 771-778.	1.2	26
141	The interaction of coagulation factor XII and monocyte/macrophages mediating peritoneal metastasis of epithelial ovarian cancer. Gynecologic Oncology, 2010, 117, 460-466.	0.6	33
142	Ovarian serous low malignant potential (borderline) tumor â€" Does â€œmicropapillaryâ€•matter?. Gynecologic Oncology, 2010, 117, 1-3.	0.6	14
143	Molecular characterization of ovarian cancer by gene-expression profiling. Gynecologic Oncology, 2010, 118, 88-92.	0.6	41
144	Development of a syngeneic mouse model of epithelial ovarian cancer. Journal of Ovarian Research, 2010, 3, 24.	1.3	45
145	Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges. Journal of Oncology, 2010, 2010, 1-20.	0.6	108
146	Cancer Testis Antigen Vaccination Affords Long-Term Protection in a Murine Model of Ovarian Cancer. PLoS ONE, 2010, 5, e10471.	1.1	42
147	Individual Cell-Based Model for In-Vitro Mesothelial Invasion of Ovarian Cancer. Mathematical Modelling of Natural Phenomena, 2010, 5, 203-223.	0.9	31
148	AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer. Cancer Research, 2010, 70, 7570-7579.	0.4	194
149	Human steroidogenic factor-1 (hSF-1) regulates progesterone biosynthesis and growth of ovarian surface epithelial cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2010, 119, 14-25.	1.2	10

#	Article	IF	Citations
150	The MÃ¼llerian HOXA10 gene promotes growth of ovarian surface epithelial cells by stimulating epithelialâ€"stromal interactions. Molecular and Cellular Endocrinology, 2010, 317, 112-119.	1.6	21
151	Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. International Journal of Biochemistry and Cell Biology, 2010, 42, 1262-1272.	1.2	63
152	Peri- and post-menopausal incidental adnexal masses and the risk of sporadic ovarian malignancy: new insights and clinical management. Gynecological Endocrinology, 2010, 26, 631-643.	0.7	24
154	miRNAs: Small but deadly. African Journal of Biotechnology, 2011, 10, 9542-9548.	0.3	0
155	Subtype Specific Elevated Expression of Hyaluronidase-1 (HYAL-1) in Epithelial Ovarian Cancer. PLoS ONE, 2011, 6, e20705.	1.1	26
156	Fallopian Tube Correlates of Ovarian Serous Borderline Tumors. American Journal of Surgical Pathology, 2011, 35, 1759-1765.	2.1	59
157	The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation. BMC Cancer, 2011, 11, 405.	1.1	48
158	Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation. Molecular Cancer, 2011, 10, 125.	7.9	40
159	Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomics. Proteomics, 2011, 11, 4677-4687.	1.3	36
160	Protein expression patterns associated with advanced stage ovarian cancer. Electrophoresis, 2011, 32, 1992-2003.	1.3	23
161	Histologic, Molecular, and Cytogenetic Features of Ovarian Cancers: Implications for Diagnosis and Treatment. Radiographics, 2011, 31, 625-646.	1.4	150
162	Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 1104-1109.	3.3	62
163	Genomic Complexity and AKT Dependence in Serous Ovarian Cancer. Cancer Discovery, 2012, 2, 56-67.	7.7	109
164	Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. Oncogene, 2012, 31, 2512-2520.	2.6	69
165	Evaluation of microsatellite instability in women with epithelial ovarian cancer. Oncology Letters, 2012, 4, 556-560.	0.8	15
166	Expression and role of the inhibitor of apoptosis protein livin in chemotherapy sensitivity of ovarian carcinoma. International Journal of Oncology, 2012, 41, 1021-1028.	1.4	10
167	Genetic and Pharmacologic Inhibition of Complement Impairs Endothelial Cell Function and Ablates Ovarian Cancer Neovascularization. Neoplasia, 2012, 14, 994-IN1.	2.3	103
168	Technical challenges and limitations of current mouse models of ovarian cancer. Journal of Ovarian Research, 2012, 5, 39.	1.3	22

#	Article	IF	Citations
169	Primary cilia and aberrant cell signaling in epithelial ovarian cancer. Cilia, 2012, 1, 15.	1.8	72
170	Epidermal growth factor modulates claudins and tight junctional functions in ovarian cancer cell lines. Histochemistry and Cell Biology, 2012, 138, 323-338.	0.8	22
171	Hox Gene Expression in Ovarian Cancer. Annals of Oncology, 2012, 23, ix68.	0.6	0
172	Proteomic characterization of ovarian cancers identifying annexinâ€‹<scp>A</scp>4, phosphoserine aminotransferase, cellular retinoic acidâ€binding protein 2, and serpin <scp>B</scp>5 as histologyâ€specific biomarkers. Cancer Science, 2012, 103, 747-755.	1.7	48
173	Increased expression of OCIA domain containing 2 during stepwise progression of ovarian mucinous tumor. Pathology International, 2012, 62, 471-476.	0.6	15
174	High serum HTATIP2/TIP30 level in serous ovarian cancer as prognostic or diagnostic marker. European Journal of Medical Research, 2013, 18, 18.	0.9	10
175	Ovarian cancer: genomic analysis. Annals of Oncology, 2013, 24, x7-x15.	0.6	29
176	Investigation of the hub genes and related mechanism in ovarian cancer via bioinformatics analysis. Journal of Ovarian Research, 2013, 6, 92.	1.3	16
177	Thrombomodulin mediates the progression of epithelial ovarian cancer cells. Tumor Biology, 2013, 34, 3743-3751.	0.8	11
178	Fallopian tube precursors of ovarian lowâ€and highâ€grade serous neoplasms. Histopathology, 2013, 62, 44-58.	1.6	238
179	Revisiting ovarian cancer preclinical models: Implications for a better management of the disease. Cancer Treatment Reviews, 2013, 39, 561-568.	3.4	24
180	Estrogen and androgen receptor expression in surface epithelium and inclusion cyst in the ovary of premenopausal and postmenopausal women. Journal of Ovarian Research, 2013, 6, 85.	1.3	6
181	STUDY OF OVARIAN CHANGES IN RATS WITH MAMMARY CARCINOMAS. Acta Medica Medianae, 2013, , 25-32.	0.0	0
182	Precursors and pathogenesis of ovarian carcinoma. Pathology, 2013, 45, 229-242.	0.3	128
183	Loss of function of Ribonuclease T2, an ancient and phylogenetically conserved RNase, plays a crucial role in ovarian tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8140-8145.	3.3	43
184	Gene Expression Analyses Support Fallopian Tube Epithelium as the Cell of Origin of Epithelial Ovarian Cancer. International Journal of Molecular Sciences, 2013, 14, 13687-13703.	1.8	32
185	Multiple Genetic Alterations within the PI3K Pathway Are Responsible for AKT Activation in Patients with Ovarian Carcinoma. PLoS ONE, 2013, 8, e55362.	1.1	33
186	The Role of microRNAs in the Tumorigenesis of Ovarian Cancer. Frontiers in Oncology, 2013, 3, 153.	1.3	85

#	Article	IF	Citations
187	Ovarian Cancer Biomarkers. Advances in Clinical Chemistry, 2014, , 25-77.	1.8	20
188	Recent Concepts of Ovarian Carcinogenesis: Type I and Type II. BioMed Research International, 2014, 2014, 1-11.	0.9	164
189	Development of a Mouse Model of Menopausal Ovarian Cancer. Frontiers in Oncology, 2014, 4, 36.	1.3	13
190	Coxsackievirus B3 infection reduces female mouse fertility. Experimental Animals, 2015, 64, 343-352.	0.7	1
191	Apatone Â® induces endometrioid ovarian carcinoma (MDAH 2774) cells to undergo karyolysis and cell death by autoschizis: A potent and safe anticancer treatment. Translational Research in Anatomy, 2015, 1, 25-39.	0.3	5
192	Expression of folate receptors alpha and beta in normal and cancerous gynecologic tissues: correlation of expression of the beta isoform with macrophage markers. Journal of Ovarian Research, 2015, 8, 29.	1.3	61
193	Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. American Journal of Surgical Pathology, 2015, 39, 1548-1557.	2.1	70
194	An Exercise Intervention During Chemotherapy for Women With Recurrent Ovarian Cancer: A Feasibility Study. International Journal of Gynecological Cancer, 2015, 25, 985-992.	1.2	43
195	Structural perspective of ARHI mediated inhibition of STAT3 signaling: An insight into the inactive to active transition of ARHI and its interaction with STAT3 and importinÎ². Cellular Signalling, 2015, 27, 739-755.	1.7	21
196	Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics, 2015, 47, 888-897.	9.4	78
197	Prognostic relevance of acquired uniparental disomy in serous ovarian cancer. Molecular Cancer, 2015, 14, 29.	7.9	15
198	Primary Peritoneal Clear Cell Carcinoma Versus Ovarian Carcinoma Versus Malignant Transformation of Endometriosis. International Journal of Surgical Pathology, 2015, 23, 211-216.	0.4	11
199	Quantifying Physical Activity and the Associated Barriers for Women With Ovarian Cancer. International Journal of Gynecological Cancer, 2015, 25, 577-583.	1.2	32
200	Do hereditary syndrome-related gynecologic cancers have any specific features?. Insights Into Imaging, 2015, 6, 545-552.	1.6	12
201	Epithelial ovarian cancer stem cells: underlying complexity of a simple paradigm. Reproduction, 2015, 149, R59-R70.	1.1	63
202	Aqueous Extract of Paris polyphylla (AEPP) Inhibits Ovarian Cancer via Suppression of Peroxisome Proliferator-Activated Receptor-Gamma Coactivator (PGC)-1alpha. Molecules, 2016, 21, 727.	1.7	23
203	Ovarian Cancer in Hereditary Cancer Susceptibility Syndromes. Surgical Pathology Clinics, 2016, 9, 189-199.	0.7	22
204	HNF1Î² drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC). Tumor Biology, 2016, 37, 4813-4829.	0.8	47

#	Article	IF	Citations
205	KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice. International Journal of Cancer, 2017, 140, 1860-1869.	2.3	24
206	Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary, with putative origin, tubes and ovaries, in high grade serous ovarian cancer. Cancer Letters, 2017, 388, 158-166.	3.2	15
207	miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma. Human Pathology, 2017, 70, 98-104.	1.1	14
208	Do some epithelial ovarian cancers originate from a fallopian tube ciliate cell lineage?. Medical Hypotheses, 2017, 107, 16-21.	0.8	6
209	Dickkopf-4 is frequently overexpressed in epithelial ovarian carcinoma and promotes tumor invasion. BMC Cancer, 2017, 17, 455.	1.1	10
210	Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube. BMC Cancer, 2017, 17, 422.	1.1	12
211	Developing a deeper insight into reproductive biomarkers. Clinical and Experimental Reproductive Medicine, 2017, 44, 159.	0.5	8
212	Systematic module approach identifies altered genes and pathways in four types of ovarian cancer. Molecular Medicine Reports, 2017, 16, 7907-7914.	1.1	2
213	Subtypes of Ovarian Cancer and Ovarian Cancer Screening. Diagnostics, 2017, 7, 12.	1.3	80
214	The Functions of MicroRNA-200 Family in Ovarian Cancer: Beyond Epithelial-Mesenchymal Transition. International Journal of Molecular Sciences, 2017, 18, 1207.	1.8	62
215	The Role of Endocrine G Protein-Coupled Receptors in Ovarian Cancer Progression. Frontiers in Endocrinology, 2017, 8, 66.	1.5	22
216	Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. , 2018, 186, 1-24.		297
217	miRNAs and ovarian cancer: An overview. Journal of Cellular Physiology, 2018, 233, 3846-3854.	2.0	150
218	Cell Origins of High-Grade Serous Ovarian Cancer. Cancers, 2018, 10, 433.	1.7	176
219	The Pathology of Pelvic-Ovarian Epithelial (Epithelial-Stromal) Tumors. , 2018, , 865-948.		1
220	Recent Insights into Mucinous Ovarian Carcinoma. International Journal of Molecular Sciences, 2018, 19, 1569.	1.8	43
221	In vivo selection reveals autophagy promotes adaptation of metastatic ovarian cancer cells to abdominal microenvironment. Cancer Science, 2019, 110, 3204-3214.	1.7	7
222	Identification of a Prognostic Signature Associated With DNA Repair Genes in Ovarian Cancer. Frontiers in Genetics, 2019, 10, 839.	1.1	21

#	Article	IF	Citations
223	Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer. Journal of Biotechnology, 2019, 297, 58-65.	1.9	32
224	A Comprehensive Review of Ovarian Serous Carcinoma. Advances in Anatomic Pathology, 2019, 26, 329-339.	2.4	40
226	Histotype-specific analysis of acid ceramidase expression in ovarian cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 855-862.	1.4	5
227	A descriptive study of the clinico-pathological and surgical characteristics of patients with primary epithelial ovarian cancer. A cross sectional study. Annals of Medicine and Surgery, 2020, 59, 254-257.	0.5	0
228	Most Commonly Mutated Genes in High-Grade Serous Ovarian Carcinoma Are Nonessential for Ovarian Surface Epithelial Stem Cell Transformation. Cell Reports, 2020, 32, 108086.	2.9	16
229	Human spermbots for patient-representative 3D ovarian cancer cell treatment. Nanoscale, 2020, 12, 20467-20481.	2.8	31
230	microRNA as Biomarker in Ovarian Cancer Management: Advantages and Challenges. DNA and Cell Biology, 2020, 39, 2103-2124.	0.9	10
231	miR-454 suppresses the proliferation and invasion of ovarian cancer by targeting E2F6. Cancer Cell International, 2020, 20, 237.	1.8	17
232	EpCAM-claudin-tetraspanin-modulated ovarian cancer progression and drug resistance. Cell Adhesion and Migration, 2020, 14, 57-68.	1.1	9
233	Histopathological Variants of Ovarian Tumors and Their Presentation in Rural Tertiary Care Center of Northern India: An Observational Study. Indian Journal of Gynecologic Oncology, 2020, 18, 1.	0.1	1
234	ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo. Experimental Cell Research, 2020, 392, 112009.	1.2	8
235	Vitamin D Suppresses Ovarian Cancer Growth and Invasion by Targeting Long Non-Coding RNA CCAT2. International Journal of Molecular Sciences, 2020, 21, 2334.	1.8	23
236	Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens. IScience, 2021, 24, 102757.	1.9	20
239	Ovulatory Factor in Ovarian Carcinogenesis. , 2008, 622, 119-128.		11
240	Animal Models of Ovarian Cancer. Cancer Treatment and Research, 2009, 149, 353-391.	0.2	15
241	The Blood-Follicle Barrier (BFB) In Disease and in Ovarian Function. Advances in Experimental Medicine and Biology, 2013, 763, 186-192.	0.8	60
242	Molecular Pathogenesis of Ovarian Cancer: An Inextricable Maze. , 2018, , 123-134.		1
243	Female reproductive system. , 2011, , 1399-1657.		1

#	Article	IF	Citations
244	Epidemiology of Ovarian, Fallopian Tube, and Primary Peritoneal Cancers. , 2004, , 326-340.		4
245	Immunohistochemical and functional biomarkers of value in female genital tract lesions. , 2009, , 999-1014.		2
246	Peritoneum and retroperitoneum. , 2007, , 279-296.		1
250	Loss of GATA4 and GATA6 Expression Specifies Ovarian Cancer Histological Subtypes and Precedes Neoplastic Transformation of Ovarian Surface Epithelia. PLoS ONE, 2009, 4, e6454.	1.1	53
251	Conditional Inactivation of p53 in Mouse Ovarian Surface Epithelium Does Not Alter MIS Driven Smad2-Dominant Negative Epithelium-Lined Inclusion Cysts or Teratomas. PLoS ONE, 2013, 8, e65067.	1.1	18
252	Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research. PLoS ONE, 2013, 8, e72162.	1.1	200
253	Current concepts in ovarian epithelial tumorigenesis: correlation between morphological and molecular data. Histology and Histopathology, 2006, 21, 81-92.	0.5	36
254	Epithelialization of mouse ovarian tumor cells originating in the fallopian tube stroma. Oncotarget, 2016, 7, 66077-66086.	0.8	13
255	Antimetastatic effects of cordycepin mediated by the inhibition of mitochondrial activity and estrogen-related receptor Î± in human ovarian carcinoma cells. Oncotarget, 2017, 8, 3049-3058.	0.8	29
256	The inhibition of cordycepin on cancer stemness in TGF-beta induced chemo-resistant ovarian cancer cell. Oncotarget, 2017, 8, 111912-111921.	0.8	11
257	Molecular signature induced by RNASET2, a tumor antagonizing gene, in ovarian cancer cells. Oncotarget, 2011, 2, 477-484.	0.8	30
258	Metabolic alterations caused by HNF1Î² expression in ovarian clear cell carcinoma contribute to cell survival. Oncotarget, 2015, 6, 26002-26017.	0.8	47
259	Loss of E-cadherin disrupts ovarian epithelial inclusion cyst formation and collective cell movement in ovarian cancer cells. Oncotarget, 2016, 7, 4110-4121.	0.8	32
260	Pinin interacts with C-terminal binding proteins for RNA alternative splicing and epithelial cell identity of human ovarian cancer cells. Oncotarget, 2016, 7, 11397-11411.	0.8	30
261	Beta-Caryophyllene Suppresses Ovarian Cancer Proliferation by Inducing Cell Cycle Arrest and Apoptosis. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 1530-1537.	0.9	23
262	Pathology of BRCA-Associated Ovarian Cancers, Including Occult Cancers. , 2008, , 29-43.		2
264	Comparative expression of caspases and annexin V in benign and malignant ovarian tumors. Journal of Cancer Research and Therapeutics, 2018, 14, 1042.	0.3	10
265	Global epidemiology, risk factors, and histological types of ovarian cancers in Trinidad. Journal of Family Medicine and Primary Care, 2019, 8, 1058.	0.3	9

#	Article	IF	Citations
266	The expression and significance of Dickkopf-1 in epithelial ovarian carcinoma. International Journal of Biological Markers, 2009, 24, 165-170.	0.7	17
267	Exploring the Histogenesis of Ovarian Mucinous and Transitional Cell (Brenner) Neoplasms and Their Relationship With Walthard Cell Nests: A Study of 120 Tumors. Archives of Pathology and Laboratory Medicine, 2008, 132, 1753-1760.	1.2	134
268	MicroRNAs as Biomarkers for Early Diagnosis, Prognosis, and Therapeutic Targeting of Ovarian Cancer. Journal of Oncology, 2021, 2021, 1-25.	0.6	13
269	FrÃ¼herkennung, Vorsorge und Prophylaxe. , 2009, , 59-69.		0
270	Loss of ANXA7 Expression is Associated with Poor Patient Survival in Ovarian Cancer. Journal of Molecular Biomarkers & Diagnosis, 2011, 02, .	0.4	3
271	The Pathology of Pelvic-Ovarian Epithelial (Epithelial-Stromal) Tumors. , 2011, , 818-895.		2
272	Homeobox Genes and Their Functional Significance in Ovarian Tumorigenesis. , 0, , .		0
273	Value of Wilms tumor gene product (WT-1) immunohistochemical expression in ovarian neoplasms. International Journal of Medicine, 2014, 2, 22.	0.1	0
274	The Histopathological Changes in Rat Ovary and Endometrium Following Long Term Clomiphene Treatment. Turkiye Klinikleri Journal of Medical Sciences, 2015, 35, 209-217.	0.1	0
275	Proliferative and angiogenic activity of endometriomas. Russian Journal of Human Reproduction, 2016, 22, 91.	0.1	2
277	Computational Design of New Analogues from Lyngbyastatin-2 against Epidermal Growth Factor Receptor (EGFR) through Molecular Docking. Journal of Pharmaceutical Research International, 0, , 1-10.	1.0	0
278	Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Women's Oncology Review, 2005, 5, 219-221.	0.0	0
279	Epithelial Ovarian Cancer. , 2005, , 473-486.		2
280	Pathology of Incipient Neoplasia. , 2005, , 69-96.		8
282	Loss of DNA mismatch repair protein hMSH6 in ovarian cancer is histotype-specific. International Journal of Clinical and Experimental Pathology, 2008, 1, 502-9.	0.5	17
283	Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas. International Journal of Clinical and Experimental Pathology, 2012, 5, 182-6.	0.5	11
285	Find the path of least resistance: Adaptive therapy to delay treatment failure and improve outcomes. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188681.	3.3	5
294	Impact of lifestyle factors on preneoplastic changes in prophylactic oophorectomies of BRCA mutation carriers. European Journal of Cancer Prevention, 2012, 21, 199-204.	0.6	6

#	Article	IF	Citations
295	Endogenous Hormones and Ovarian Cancer: Epidemiology and Current Hypotheses. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 98-107.	1.1	238
296	Peritoneal and Subperitoneal Stroma May Facilitate Regional Spread of Ovarian Cancer. Clinical Cancer Research, 2005, 11, 113-122.	3.2	89
297	Ovarian Cancer Pathology. , 2022, , 57-85.		0
299	Gynecologic Pathology. , 2023, , 45-56.		0